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Objective. 1H MR spectroscopy (MRS) is widely performed for assessment of brain tumours and is considered a highly sensitive
technique capable of diﬀerentiating benign from malignant conditions and tumour grading. Method.W ep r e s e n tac a s eo fa
69yearold woman who was suspected to have gliomatosis on MRI. Results. MRS performed using single voxel and chemical
shift/multivoxel techniques was within normal limits. A repeat scan 6 months later showed progressive disease, and biopsy was
performed that proved the diagnosis of glioblastoma. Conclusion. Normal MRS in a patient with suspicion of gliomatosis on MRI
should not reassure clinicians into assuming a benign aetiology or a good prognosis in short term.
1.Introduction
MRS is widely performed as a research and diagnostic tool
for assessment of brain tumours. Establishing a type and
grade of intracranial tumour is often diﬃcult with conven-
tional magnetic resonance imaging (MRI), which is a princi-
palimagingmodalityforitsevaluation.MRSisanoninvasive
method of acquiring information about metabolic activity of
the brain tissue. It can be routinely obtained at the time of
diagnostic MRI.
There are several reports discussing the role of MRS in
diﬀerentiating benign from malignant gliomas and radiation
necrosis from tumour recurrence. This heavily relies on the
high sensitivity of MRS in detecting metabolic abnormalities
in brain tumours, particularly malignant ones. However,
there is not much literature regarding negative predictive
value or sensitivity of MRS in suspected brain tumours or
gliomatosis cerebri.
We report a case of an intra-axial lesion, which had MRI
appearances consistent with a low-grade diﬀuse glioma or
gliomatosis, but MRS ﬁndings were entirely within limits for
a normal brain tissue. A few months later, the histological
analysis of the lesion, following biopsy, conﬁrmed the
diagnosis of glioblastoma multiforme (GBM).
2.CaseReport
A 69-year-old woman presented with a 14-month history
of intermittent fornication in the distribution of the left
mandibular (V3) division of the trigeminal nerve. MRI
scan identiﬁed a presence of an ill-deﬁned, diﬀuse lesion,
involving cortex and subcortical white matter of the left
occipital and parietal lobes extending into the frontal lobe,
with only slight mass eﬀect and relative preservation of
underlying anatomy with no postcontrast enhancement. The
M R If e a t u r e sw e r es u g g e s t i v eo fl o w - g r a d ed i ﬀuse glioma or
gliomatosis cerebri. After ﬁve months time follow-up MR
scan with MRS (1.5T Siemens Avanto) using 2D CSI and
single voxel (SV) technique (TE of 135ms, TR of 1500ms)
wasperformed.TheanalysisofMRSﬁndings wasdone using
the standard software provided by the manufacturer. The
MRI scan again conﬁrmed the presence of extensive signal
abnormality,whichunchangedinsizefromthepreviousscan
(Figure 1). The MRS (SV and CSI) through the abnormal2 Case Reports in Radiology
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Figure 1: Coronal FLAIR (a) and axial T2 weighted images (b) showing extent of the lesion on MR scan taken at the time of MRS.
areas was extensively assessed but showed no alteration in
choline and N-acetyl aspartate (NAA) peaks compared to
normal brain tissue and was entirely within normal limits
(Figures 2 and 3).
The patient presented six months later with 2 weeks
history of partial seizures, involving the right upper and
lower limbs. Repeat cranial MRI scan revealed signiﬁcant
progression of the lesion into the occipital region and an
increase in the mass eﬀect. An area of enhancement in
the left parietal lobe was also present, measuring 19 ×
18mm (Figure 4). The patient subsequently went on to
have a biopsy. The pathology conﬁrmed the presence of
glioblastoma multiforme (GBM).
3. Discussion
Established MRS applications in cerebral tumours include
diﬀerentiation between brain abscess and cystic tumours,
low-grade and high-grade gliomas, gliomatosis cerebri,
oedema and tumour inﬁltration, recurrent tumour, and
radionecrosis and used in a stereotactic biopsy planning of
brain lesions [1]. MRS literature in brain tumours is based
on the assumption that MRS is highly sensitive technique
and is highly capable of ﬁnding abnormal metabolic spectra
in tumours and normal tissues, and questions are usually
raised regarding its speciﬁcity. We found hardly any studies
that raise questions on the inability of MRS to ﬁnd abnormal
metabolites in abnormal looking lesions on MRI. There
were no deﬁnite false negative rates of MRS reported. There
are, however, some controversies in relation to MRS in
gliomatosis cerebri.
The most frequently assessed chemical ratios in diag-
nosis of intracranial tumours is Choline/Creatine (Cho/Cr),
Choline/N-acetyl aspartate (Cho/NAA), and Lactate/Crea-
tine (Lac/Cr) ratios. As compared to the normal brain tissue,
tumours characteristically present a decreased NAA and
increased Cho levels. NAA is normally present in neurons
and neuronal injury and replacement of neurons by tumour
cells cause reduction in NAA levels. Increased Cho levels are
due to breakdown of membrane phospholipids caused by a
rapid cell turnover in neoplastic lesions. The usual ﬁnding in
neoplastic lesions is a Cho/NAA ratio greater than one [1].
The Cho/Cr and Cho/NAA ratios usually vary according to
grades of gliomas [2].
It is widely believed that adding MRS to conventional
MRI protocols improves accuracy of diagnosis of intra-
axial tumours. In 2004, Lukas et al. reported the accuracy
increased to 94% using long echo time (TE) and to 96%
using short TE [3, 4]. Galanaud et al. [5]p r o p o s e da
diagnostic ﬂow chart for multimodal analysis of brain
tumours, that included MR and MRS ﬁndings, which
correctly identiﬁed 91% of intracranial contrast enhancing
lesions and 87% of noncontrast enhancing lesions, proving
that the addition of MRS to conventional MRI increases
signiﬁcantly the proportion of correct diagnoses of brain
tumours. A study by Preul et al. using a pattern-recognition
analysis of biochemical information obtained from MRS
correctly classiﬁed 104 of 105 spectra of ﬁve most common
types of adult supratentorial brain tumours and a normal
brain tissue [6]. These studies largely emphasise the high
sensitivity of MRS in brain tumours.
Due to high sensitivity of MRS, it has also been shown
to be able to diﬀerentiate benign from malignant conditions.
Vuori et al. proved that loss of NAA and increase of Cho were
more pronounced in low-grade gliomas than in focal cortical
developmental malformations [7].
The value of MRS in gliomatosis cerebri is more contro-
versial. MRI ﬁndings have been reported to be nonspeciﬁc
and can underestimate the extent of the lesion [8]. The
diﬀerential diagnosis includes ischaemia, multiple sclero-
sis, encephalitis, leucodystrophies, and subacute sclerosing
panencephalitis [9, 10]. Gliomatosis is believed to be distinct
from other gliomas due to the absence of inﬁltration and
preservation of neuronal structures. Overall, there have
been limited studies of gliomatosis cerebri with MRS.
MRS has been shown to be helpful in detecting abnormal
metabolites, thus helping in the diagnosis. In keeping with
its high sensitivity, MRS has been used to assess the extentCase Reports in Radiology 3
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Figure 2: MRS CSI spectra (grid-2A) showing no alteration in metabolite ratios between normal (Figure 2(b)) and abnormal signal area of
the brain (Figure 2(c)).
(a) (b)
Figure 3: MRSSVspectrum fromabnormal signal brain area(Figures 3(a) and3(b)) showingNAAand Cholinelevels within normal limits.
(a) (b) (c)
Figure 4: Axial T2 (a), coronal FLAIR (b), and axial T1 post-Gadolinium image (c) from 6-months followup MR scan, showing signiﬁcant
progression of the lesion and a new area of enhancement in the left parietal lobe.4 Case Reports in Radiology
of neoplastic inﬁltration more accurately than MRI. In
addition, MRS has also been shown to be helpful in grading
of these lesions [11]. However, there is no consensus about
the associated characteristic metabolic abnormalities found
in this condition. Some studies report normal choline peaks
[11, 12], while others described moderate increase in this
metabolite in gliomatosis cerebri [13, 14]. However, the drop
in NAA peak is a more consistent described feature [15].
However, we have not come across any reports documenting
MRS ﬁndings within normal limits even in gliomatosis
cerebri.
We have no clear explanation why MRS was normal in
our patient. However, given the paucity of reported MRS
ﬁndings in gliomatosis cerebri in the literature compared to
other gliomas, we wonder if it can be to the extent of “within
normal limits” as in our patient. Our ﬁndings raise questions
about the sensitivity and negative predictive value of MRS in
gliomatosis cerebri and its ability to diﬀerentiate gliomatosis
cerebri from other benign cerebral conditions. We do not
havehistology resultsatthe time of MRSand no MRSdata at
the time of biopsy, as these were 6 months apart. However, it
is likely that the abnormality represented a low grade glioma
that dediﬀerentiated into high-grade glioma a few months
later. Hence, it can be reasonably assumed that the MRS data
represents low-grade glioma that lasted for a while and was
seen as abnormal appearance on MRI, but the MRS ﬁndings
have been unhelpful in predicting how soon this may occur.
4. Conclusion
While it is widely believed that MRS is highly sensitive in
gliomas, the current case illustrates that MRS may show
normal spectrum in a low-grade glioma or gliomatosis
cerebri that can potentially change into a GBM in just a
few months time. Therefore, a normal spectrum should not
reassure clinicians into assuming a benign aetiology and
patients should still be followed up at usual intervals with
equal emphasis on other imaging and clinical ﬁndings.
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